This combination significantly increased CD4+ and CD8+ T cell infiltration within tumor tissue, markedly enhanced the cytotoxic activity of tumor-specific cytotoxic T lymphocytes (CTLs), and reversed both IL-2 depletion and elevated PD-L1 expression induced by sorafenib intervention. This evidence concerns the gene CD4 and neoplasm.